Dr. Raez outlined that osimertinib + amivantamab increases PFS by 30 % and OS by 25 % at 42 months, lorlatinib delivers up‑to‑five‑year PFS superiority over alectinib for ALK‑positive disease, repotrectinib confers durable, well‑tolerated PFS benefits in ROS1‑rearranged tumors, and trastuzumab deruxtecan achieves high response rates in HER2‑mutant NSCLC. He stressed that combination regimens, emerging bispecific antibodies, and improved biomarkers are key to further advances.